Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
US7025970B2 · kind B2 · utility
2Cited by
2References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2003 |
| Grant date | Apr 11, 2006 |
| Priority date | — |
| Expiry date | Mar 25, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.